Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'h,3'h)-trione
2. Azd-0914
3. Azd0914
4. Etx-0914
5. Etx0914
1. 1620458-09-4
2. Azd0914
3. Azd-0914
4. Zoliflodacin [usan]
5. Etx0914
6. Etx-0914
7. Fwl2263r77
8. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'h,3'h)-trione
9. Unii-fwl2263r77
10. Zoliflodacin(azd0914)
11. Zoliflodacin (usan/inn)
12. Zoliflodacin [inn]
13. Zoliflodacin [who-dd]
14. Azd 0914 - Bio-x
15. Chembl3544978
16. Schembl15879500
17. Gtpl10875
18. Azd0914etx0914
19. Ext0914
20. Bdbm139376
21. Dtxsid101028418
22. Azd 0914
23. Ex-a2620
24. Ext-0914
25. Etx0914; Azd0914; Zoliflodacin
26. Db12817
27. Ac-35757
28. Ba164192
29. Hy-17647
30. Cs-0016917
31. D11726
32. Us8889671, 5
33. Q27278240
34. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((s)-4-methyl-2-oxooxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(1'h,3'h)-trione
35. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((s)-4-methyl-2-oxooxazolidin-3-yl)-2,4,4a,6-tetrahydro-1h,1'h-spiro[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(3'h)-trione
36. (4'r,6's,7's)-17'-fluoro-4',6'-dimethyl-13'-[(4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione
37. (7s,11r,13s)-3-((4s)-2-oxo-4-methyltetrahydrooxazole-3-yl)-9-fluoro-11,13-dimethyl-8,7-(ethanoxymethano)-7,8,1',2',3',4'-hexahydrospiro[isoxazolo[4,5-g]quinoline-6(5h),5'(6'h)-pyrimidine]-2',4',6'-trione
38. Spiro(isoxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5(6h),5'(2'h)-pyrimidine)-2',4',6'(1'h,3'h)-trione, 11-fluoro-1,2,4,4a-tetrahydro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-3-oxazolidinyl)-, (2r,4s,4as)-
Molecular Weight | 487.4 g/mol |
---|---|
Molecular Formula | C22H22FN5O7 |
XLogP3 | 1.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 1 |
Exact Mass | 487.15032622 g/mol |
Monoisotopic Mass | 487.15032622 g/mol |
Topological Polar Surface Area | 143 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 962 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of gonococcal infection
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
ABOUT THIS PAGE
A Zoliflodacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zoliflodacin, including repackagers and relabelers. The FDA regulates Zoliflodacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zoliflodacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Zoliflodacin supplier is an individual or a company that provides Zoliflodacin active pharmaceutical ingredient (API) or Zoliflodacin finished formulations upon request. The Zoliflodacin suppliers may include Zoliflodacin API manufacturers, exporters, distributors and traders.
Zoliflodacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zoliflodacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zoliflodacin GMP manufacturer or Zoliflodacin GMP API supplier for your needs.
A Zoliflodacin CoA (Certificate of Analysis) is a formal document that attests to Zoliflodacin's compliance with Zoliflodacin specifications and serves as a tool for batch-level quality control.
Zoliflodacin CoA mostly includes findings from lab analyses of a specific batch. For each Zoliflodacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zoliflodacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Zoliflodacin EP), Zoliflodacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zoliflodacin USP).
LOOKING FOR A SUPPLIER?